Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab
Author:
Publisher
Elsevier BV
Subject
General Medicine,Otorhinolaryngology,Surgery
Reference32 articles.
1. Platinum-based chemotherapy plus cetuximab in head and neck cancer;Vermorken;N Engl J Med,2008
2. NCCN Clinical Practice Guidelines in Oncology, Head and Neck (Version1.2019).
3. Nivolumab for recurrent squamous-cell carcinoma of the head and neck;Ferris;N Engl J Med,2016
4. Efficacy and safety of nivolumab in 100 patients with recurrent or metastatic head and neck cancer - a retrospective multicentre study;Okamoto;Acta Otolaryngol,2019
5. Nivolumab-induced recurrence of rheumatoid arthritis in a patient with metastatic gastric adenocarcinoma;Nishikawa;Clin Drug Investig,2019
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Diagnostic and prognostic nomograms for laryngeal carcinoma patients with lung metastasis: a SEER-based study;European Archives of Oto-Rhino-Laryngology;2024-04-07
2. Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Tertiary Centre’s Real-World Experience;Current Oncology;2023-09-29
3. Hyperprogressive disease in patients suffering from solid malignancies treated by immune checkpoint inhibitors: A systematic review and meta-analysis;Frontiers in Oncology;2022-08-03
4. 頭頸部癌免疫療法のエッセンス;Nippon Jibiinkoka Tokeibugeka Gakkai Kaiho(Tokyo);2022-07-20
5. Nivolumab in platinum-refractory head-and-neck cancers: A retrospective observational audit from a tertiary cancer center;Cancer Research, Statistics, and Treatment;2022-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3